The small intestinal bacterial overgrowth (SIBO) diagnostics market size is projected to reach US$ 266.81 million by 2031 from US$ 155.60 million in 2023. The market is expected to register a CAGR of 4.8% during 2023–2031. Next-generation sequencing technologies to diagnose SIBO is likely to remain key trend in the market.
Increasing incidence of SIBO, rising demand for non-invasive diagnostics tests, and technological advancements in diagnostic tests are fueling the growth of the small intestinal bacterial overgrowth (SIBO) diagnostics market. In addition, the growing focus on gut health and digestive health, expansion of healthcare infrastructure, and growing awareness and education about SIBO among healthcare professionals and patients are driving the growth of the small intestinal bacterial overgrowth (SIBO) diagnostics market
Geographically, Asia Pacific is expected to register highest CAGR in the forecast period 2023-2031. India is among the fastest-developing nations in the world and is among the top leading countries of Asia Pacific. India is the fastest developing country in the Asia Pacific region. It has well-established companies operating in the biotechnology and medical device industry. Also, the a rising number of startups that are introducing laboratory equipment that utilizes the latest technologies. Whereas, rising cases of diarrhea, SIBO, and gastrointestinal diseases widen growth opportunities for India's small intestinal bacterial overgrowth (SIBO) diagnostics market. Similarly, the increasing number of hospitals and diagnostics laboratories across the country is likely to increase demand for modernized diagnostic instruments and equipment, offering a favorable environment for India small intestinal bacterial overgrowth diagnostics market during the forecast period.
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market: Strategic Insights
Irritable bowel syndrome (IBS) is the commonly diagnosed gastrointestinal disorder with abdominal pain and altered bowel habits resulting with associated symptoms such as bloating, malabsorption, and systemic symptoms. Crohn's disease and ulcerative colitis are types of IBS. It causes swelling in the digestive tract, which can cause abdominal pain, diarrhea, fatigue, weight loss, and malnutrition. According to MedlinePlus, Crohn's disease is most prevalent in Western Europe and North America, with a prevalence rate of 100 to 300 per 100,000 people. According to the Medscape data, the incidence of ulcerative colitis in the US is 10.4–12 cases per 100,000 people, and the prevalence rate is 35–100 cases per 100,000 people. As compared to Crohn disease, ulcerative colitis is three times more common. IBD is thought to be a result of a multitude of environmental and bacterial interactions with immune-mediated factors in a genetically susceptible host. The increasing prevalence of IBS across the world is due to the changing lifestyle and dietary habits. Small intestinal bacterial overgrowth (SIBO) is widely associated with the IBS. Thus increasing prevalence of IBS fuelis the growth of the SIBO diagnostics market as it increases the prevalence of SIBO.
The growing technological developments in the field of medical devices have offered various innovative products to diagnose several complex human health conditions. Thus, to diagnose SIBO, an innovative orally ingested capsule technology is in the developmental process. It is designed in a way to measure in vivo hydrogen and carbon-di-oxide after ingestion of a carbohydrate meal and provide a technologically updated alternative to the current breath hydrogen test. It is expected that the capsule technology will help in diagnosing samples of small bowel bacteria. Thus, the introduction of capsule technology is likely to emerge in the coming future and contribute to direct and accurate evaluation of SIBO and offer vital growth opportunities for the market’s growth.
Key segments that contributed to the derivation of the small intestinal bacterial overgrowth (SIBO) diagnostics market analysis are product, and end user.
The geographic scope of the small intestinal bacterial overgrowth (SIBO) diagnostics market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the market. North America is the largest market in the forecast period due to the increasing incidence of SIBO in the countries, growing government support, and increasing number of product introductions. In addition, rising demand for advanced diagnostic infrastructure is also likely to accelerate market growth during the forecast period. The US is the largest and fastest-growing country for the small intestinal bacterial overgrowth (SIBO) diagnostics market in the global market. The market's growth is primarily attributed to the increasing prevalence of conditions such as immunodeficiency syndromes and pancreatic exocrine insufficiency amongst others. Growing prevalence of risk factors associated with the SIBO are also expected to drive the prevalence of the condition, which will eventually offer favorable environment for growth of US small intestinal bacterial overgrowth diagnostics market
The regional trends and factors influencing the Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
Report Attribute | Details |
---|---|
Market size in 2023 | US$ 155.60 Million |
Market Size by 2031 | US$ 266.81 Million |
Global CAGR (2023 - 2031) | 4.8% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By Diagnosis
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
The Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the small intestinal bacterial overgrowth (SIBO) diagnostics market are listed below:
The “Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
North America dominated the small intestinal bacterial overgrowth (SIBO) diagnostics market in 2023.
Increasing Prevalence of Irritable Bowel Syndrome (IBS) and SIBO and advantages of breath test are among the most influential factors responsible for the market growth.
Next-generation sequencing technologies to diagnose SIBO is likely to remain key trends in the small intestinal bacterial overgrowth (SIBO) diagnostics market.
Genova Diagnostics, SIBO Diagnostics, Commonwealth Diagnostics International, Aerodiagnostics, LLC, SIBOTest, Metabolic Solutions, Inc., Pivotal Diagnostics, DirectLabs, LLC, Vibrant Wellness, and Health Associates Medical Group are among the key players operating in the market.
The small intestinal bacterial overgrowth (SIBO) diagnostics market is estimated to reach US$ 226.81 million in 2031.
The small intestinal bacterial overgrowth (SIBO) diagnostics market is anticipated to record a CAGR of 4.8% during 2023–2031.